nivolumab,relatlimab
bms
['nsclc', 'nivo', 'nivo+rela', 'lung', 'sclc', 'improve ', 'relatlimab', 'neopredict']
relatlimab (anti-lag3) holds promise to improve outcome in nsclc patients. great to see our nivo+rela neoadjuvant neopredict-lung trial being cited in the future of immunotherapy by natasha leighl #esmo2022 
MD MSc, Thoracic Oncology & Respiratory Medicine, master in hospital and health care management Hasselt - Belgium - PhD candidate Amsterdam/Leiden - he/him